DONATE TODAY
To Increase Patient Access
End Brain Cancer Mobile App to download your number one tool for navigating this disease.
YES! I'm Interested.

Are you or a loved one living with

METASTATIC NON-MUTATED NSCLC?

(Non small Cell Lung Cancer)

If so, would you like to participate in a paid online survey?
YES! I'm Interested.

The Basics

The firm conducting this research, is an independent market research agency and consultancy. The research is sponsored by a life sciences company. The client complies with all laws that protect your personal information and the following market research codes of conduct: EphMRA, Insights Association, BHBIA, and ICC/ESOMAR.

This study will require participation in an interview that will last for 60 minutes. It will also require access to a computer and Internet connection and Web browser.

Please be assured that we are not selling anything, and that the information gathered will remain confidential and be used for research purposes only. If you qualify for this study, you will be compensated with the amount noted in your invitation email. This compensation is not intended to reward you for use of any products which may be mentioned in the study or induce you to use any such products, but rather to understand your views.

You may withdraw from the market research at any time, and you will have the right to withhold information, i.e., not answer a question, should you wish to.
Virtue Research logo
People diagnosed with Non Mutated, Non-small Cell Lung Cancer within the last three years are invited to participate in a paid online survey that will help us understand the treatment and management of this cancer.

This study will require participation for 10-15min surveys for up to 2 weeks (60 mins total). It will also require access to a computer and Internet connection with a Web browser.
YES! I'm Interested.
For More Information:
Shreya Prakash
425-436-8688 
shreya@endbraincancer.org
Hope logos

ENDBRAINCANCER INITIATIVE | CHRIS ELLIOTT FUND

Enhancing patient outcomes by expanding FDA-approved treatment modalities and fueling research in the pharma/bio/life sciences, device & diagnostic industries and by closing the existing GAP from initial diagnosis to IMMEDIATE AND EXPANDED ACCESS to specialists, researchers, advanced & innovative treatments, clinical trials and critical care with the ultimate goal of improving patient outcomes through updating and improving WHO & NCCN Guidelines and clinical practices related to Standard of Care for brain cancer patients.

TAX ID:26-2185614
DONATE
corporate partners
upcoming events
resources
About us
envelopephonemap-markerpointer-right
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram